HealthTech & Biotechnology AI Medicine

Exscientia

AI-Driven Precision Drug Design and Synthesis

Valuation / Scale $1.2 Billion

Funding Raised $500 Million

Founded 2012

Headquarters Oxford, United Kingdom

About Exscientia

Exscientia uses AI platforms to automate drug discovery, engineering patient-first candidate molecules with high target affinity.

🇬🇧

Founder of Exscientia

Professor Andrew Hopkins DPhil CBE is the founder of Exscientia, the Oxford biotech that created the first AI-designed m...

VERIFIED FACTS

What is Exscientia's current valuation?

Exscientia is valued at approximately $1.2 Billion, having raised a total of $500 Million in venture financing.

Who founded Exscientia and where is it headquartered?

Exscientia was founded in 2012 by Andrew Hopkins with headquarters in Oxford, United Kingdom.

What industry does Exscientia operate in and what does it do?

Exscientia operates within the HealthTech & Biotechnology sector. AI-Driven Precision Drug Design and Synthesis

How much funding has Exscientia raised to date?

Exscientia has secured approximately $500 Million across institutional equity rounds and growth capital.